drugset / Trial / NCT02078193
Efficacy of Belatacept in Reducing DSA
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).
Timeline
- Start
- 2013-11
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belatacept | Protein / enzyme biologic | 5 mg/kg | — |
Indications
No indication recorded.